New cell therapy targets Hard-to-Treat cancers
NCT ID NCT07614048
First seen May 30, 2026 · Last updated Jun 13, 2026 · Updated 4 times
Summary
This treatment program is for people with advanced pancreatic or colorectal cancer that has a specific genetic change called KRAS G12D. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack the cancer, and then give them back. The goal is to control the disease, not cure it, and patients receive chemotherapy beforehand to prepare the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.